We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
203.21%
This Fund
S&P 500
This Quarter
Est. Return
+42.6%
1 Year Est. Return
+203.21%
3 Year Est. Return
+364.25%
5 Year Est. Return
+595.91%
10 Year Est. Return
+10,683%
AUM
$1.65B
AUM Growth
+$529M
(+47%)
Cap. Flow
+$107M
Cap. Flow
% of AUM
6.48%
Top 10 Holdings %
Top 10 Hldgs %
60.74%
Holding
37
New
2
Increased
17
Reduced
12
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$49.2M |
| 2 |
SI-BONE Inc
SIBN
|
+$39.6M |
| 3 |
Tandem Diabetes Care
TNDM
|
+$36.1M |
| 4 |
APGE
Apogee Therapeutics
APGE
|
+$31.9M |
| 5 |
GeneDx Holdings
WGS
|
+$30.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$62M |
| 2 |
Axogen
AXGN
|
+$50.6M |
| 3 |
PVLA
Palvella Therapeutics
PVLA
|
+$25.4M |
| 4 |
Wave Life Sciences
WVE
|
+$13.4M |
| 5 |
Vera Therapeutics
VERA
|
+$12.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NeoGenomics
NEO
$2.27B
| $179M | 10.89% |
12,279,523
+2,549,545
| +26% | +$24.6M |
|
|
2
SI-BONE Inc
SIBN
$825M
| $133M | 8.06% |
8,127,985
+2,774,795
| +52% | +$39.6M |
|
|
3
Axogen
AXGN
$2.54B
| $127M | 7.72% |
2,748,361
-1,254,407
| -31% | -$50.6M |
|
|
APGE
4
DELISTED
Apogee Therapeutics
APGE
| $123M | 7.51% |
930,289
+353,605
| +61% | +$31.9M |
|
|
PVLA
5
Palvella Therapeutics
PVLA
$2.18B
| $118M | 7.17% |
771,901
-208,857
| -21% | -$25.4M |
|
6
Twist Bioscience
TWST
$8.26B
| $74.9M | 4.55% |
727,933
-150,915
| -17% | -$9.82M |
|
|
7
Enliven Therapeutics
ELVN
$4.21B
| $69.1M | 4.2% |
1,360,750
+1,158,883
| +574% | +$49.2M |
|
8
Guardant Health
GH
$21.8B
| $66.3M | 4.03% |
441,586
+161,287
| +58% | +$17.5M |
|
9
908 Devices
MASS
$401M
| $54.7M | 3.32% |
6,282,804
+210,241
| +3% | +$1.61M |
|
10
Amylyx Pharmaceuticals
AMLX
$3.61B
| $54.3M | 3.3% |
3,023,256
-167,389
| -5% | -$2.59M |
|
|
11
GeneDx Holdings
WGS
$2.58B
| $53.8M | 3.27% |
783,923
+540,996
| +223% | +$30.7M |
|
12
Simulations Plus
SLP
$373M
| $51.1M | 3.11% |
2,792,677
+159,854
| +6% | +$2.46M |
|
|
13
Tandem Diabetes Care
TNDM
$1.33B
| $51.1M | 3.1% |
3,383,553
+2,068,838
| +157% | +$36.1M |
|
|
CRNX
14
DELISTED
Crinetics Pharmaceuticals
CRNX
| $50.9M | 3.1% |
1,360,866
+271,196
| +25% | +$10.1M |
|
15
Neuropace
NPCE
$498M
| $45.5M | 2.76% |
2,861,167
+401,201
| +16% | +$6.46M |
|
16
Edgewise Therapeutics
EWTX
$4.71B
| $44.5M | 2.7% |
1,095,171
+93,325
| +9% | +$3.22M |
|
17
AnaptysBio
ANAB
$1.65B
| $39.3M | 2.39% |
582,004
+16,573
| +3% | +$1M |
|
18
Trevi Therapeutics
TRVI
$2.37B
| $39.1M | 2.38% |
+2,097,215
| New | +$30.5M |
|
|
SEPN
19
Septerna Inc
SEPN
$1.77B
| $32.3M | 1.96% |
963,260
+230,400
| +31% | +$6.54M |
|
20
TriSalus Life Sciences
TLSI
$293M
| $29.8M | 1.81% |
6,552,491
+1,485,664
| +29% | +$5.9M |
|
|
TECX
21
Tectonic Therapeutic
TECX
$596M
| $27.5M | 1.67% |
800,726
+152,983
| +24% | +$4.49M |
|
22
Health Catalyst
HCAT
$130M
| $25.5M | 1.55% |
12,810,861
-67,839
| -0.5% | -$97.9K |
|
23
Butterfly Network
BFLY
$1.99B
| $22.2M | 1.35% |
2,642,404
-17,763
| -0.7% | -$92K |
|
24
Establishment Labs
ESTA
$2.22B
| $21.2M | 1.29% |
246,577
-61,161
| -20% | -$4.39M |
|
25
Vaxcyte
PCVX
$8.86B
| $20.1M | 1.22% |
345,157
+203,373
| +143% | +$11M |
|
Similar funds
AAM
NPA
SOS
BCM
BFO
AAG
MCIL
TIM
First Light Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, First Light Asset Management held 37 positions worth $1.65B, up 47% from $1.12B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Light Asset Management deployed $107M of net new capital in Q2 2026, opening 2 new positions and adding to 17 existing holdings. Its largest new stake was Trevi Therapeutics: 2,097,215 shares worth $39.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Axogen, an estimated $50.6M trimmed.
- First Light Asset Management's largest Q2 2026 buy was Trevi Therapeutics: 2,097,215 shares worth $39.1M.
- First Light Asset Management added most to Enliven Therapeutics in Q2 2026, an estimated $49.2M increase.
- First Light Asset Management's biggest Q2 2026 reduction was Axogen, cutting an estimated $50.6M.
- First Light Asset Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $62M.
- First Light Asset Management's ten largest holdings make up 61% of its $1.65B portfolio in Q2 2026.
- First Light Asset Management opened 2 new positions and closed 6 in Q2 2026.
- First Light Asset Management's portfolio value rose 47% quarter-over-quarter to $1.65B.
Based on First Light Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.